Medical therapy for differentiated thyroid carcinoma

Endocr Rev. 1994 Aug;15(4):500-15. doi: 10.1210/edrv-15-4-500.

Abstract

While some of the studies with new therapeutic modalities are encouraging, all are in their early experimental phases. It is likely that better understanding of the molecular basis for differentiated thyroid carcinoma will lead to new therapy in the next decade.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Papillary, Follicular / secondary
  • Carcinoma, Papillary, Follicular / therapy*
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunotherapy
  • Iodine Radioisotopes / therapeutic use
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Thyroid Neoplasms / therapy*
  • Thyroxine / therapeutic use

Substances

  • Antineoplastic Agents
  • Iodine Radioisotopes
  • Thyroxine